Clinical trial
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects (11038)
NCT02981966 is registered in ClinicalTrials.gov with The University of Texas Health Science Center at San Antonio as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects (11038)
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- May 23, 2019
- Completion date
- May 31, 2023
- Enrollment
- 32 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.